221 related articles for article (PubMed ID: 20043752)
1. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
Bender MA; Kumarasamy N; Mayer KH; Wang B; Walensky RP; Flanigan T; Schackman BR; Scott CA; Lu Z; Freedberg KA
Clin Infect Dis; 2010 Feb; 50(3):416-25. PubMed ID: 20043752
[TBL] [Abstract][Full Text] [Related]
2. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Wandeler G; Gerber F; Rohr J; Chi BH; Orrell C; Chimbetete C; Prozesky H; Boulle A; Hoffmann CJ; Gsponer T; Fox MP; Zwahlen M; Egger M;
Antivir Ther; 2014; 19(5):521-5. PubMed ID: 24296645
[TBL] [Abstract][Full Text] [Related]
5. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Brennan AT; Maskew M; Ive P; Shearer K; Long L; Sanne I; Fox MP
J Int AIDS Soc; 2013 Nov; 16(1):18794. PubMed ID: 24256692
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of ART in resource-limited countries.
Loubiere S; Meiners C; Sloan C; Freedberg KA; Yazdanpanah Y
Curr Opin HIV AIDS; 2010 May; 5(3):225-31. PubMed ID: 20539078
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
10. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
[TBL] [Abstract][Full Text] [Related]
11. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
von Wyl V; Cambiano V; Jordan MR; Bertagnolio S; Miners A; Pillay D; Lundgren J; Phillips AN
PLoS One; 2012; 7(8):e42834. PubMed ID: 22905175
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Tang MW; Rhee SY; Bertagnolio S; Ford N; Holmes S; Sigaloff KC; Hamers RL; de Wit TF; Fleury HJ; Kanki PJ; Ruxrungtham K; Hawkins CA; Wallis CL; Stevens W; van Zyl GU; Manosuthi W; Hosseinipour MC; Ngo-Giang-Huong N; Belec L; Peeters M; Aghokeng A; Bunupuradah T; Burda S; Cane P; Cappelli G; Charpentier C; Dagnra AY; Deshpande AK; El-Katib Z; Eshleman SH; Fokam J; Gody JC; Katzenstein D; Koyalta DD; Kumwenda JJ; Lallemant M; Lynen L; Marconi VC; Margot NA; Moussa S; Ndung'u T; Nyambi PN; Orrell C; Schapiro JM; Schuurman R; Sirivichayakul S; Smith D; Zolfo M; Jordan MR; Shafer RW
J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S70-7. PubMed ID: 23687292
[TBL] [Abstract][Full Text] [Related]
17. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
Rosen S; Long L; Fox M; Sanne I
J Acquir Immune Defic Syndr; 2008 Jul; 48(3):334-44. PubMed ID: 18545151
[TBL] [Abstract][Full Text] [Related]
18. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
19. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
[TBL] [Abstract][Full Text] [Related]
20. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.
Walensky RP; Wood R; Ciaranello AL; Paltiel AD; Lorenzana SB; Anglaret X; Stoler AW; Freedberg KA;
PLoS Med; 2010 Dec; 7(12):e1000382. PubMed ID: 21209794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
